- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06377943
The Interaction Between Resting Metabolic Rate, Physical Activity and Thyroid Hormone in Females
August 11, 2025 updated by: John R. Speakman, Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
This Study is focused on the interaction between resting metabolic rate (RMR), physical activity (PA), and thyroid hormones (TH).
TH controls almost all the cell activities of the body so, it is known as one of the major regulatory hormones.
This is the reason for individuals who suffer from thyroid disorders show abnormal metabolism.
Recently it was suggested that interindividual variations in thyroid hormone levels also influence daily physical activity.
Study Overview
Status
Completed
Conditions
Detailed Description
In this study, investigators will recruit adult females with a BMI ≥18.5.
After the screening process, eligible volunteers will undergo certain measurements including body composition, resting metabolism daily physical activity, thyroid hormone levels, and total energy expenditure.
The investigators will access the changes in resting metabolism and daily physical activities with the differences in thyroid hormone levels.
Study Type
Observational
Enrollment (Actual)
42
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518000
- Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Sampling Method
Non-Probability Sample
Study Population
The study participants are adult healthy females.
Description
Inclusion Criteria:
- Female age ≥18;
- BMI≥18.5
Exclusion Criteria:
- Intended weight change exceeding 2kg within the past three months;
- Having any special medical diets or having eating disorders;
- Pregnant women or breastfeeding women;
- People who have metal implants in their bodies;
- Patients with metabolic diseases, infectious diseases, and genetic disorders such as hypothyroidism, and hyperthyroidism;
- Patients with a personal or family history of medullary thyroid carcinoma (MTC), or patients with rare type 2 multiple endocrine tumor syndrome (MEN2); People with a fear of needles (Trypanophobia), claustrophobia; People who are fear of blood (Hemophobia) or pathological hypotension;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight
Time Frame: Measurements will take at the first day of the visit
|
Subjects will be asked to fast overnight and weight will be measured using a calibrated Seca body weight scale first thing in the morning on subjects wearing light clothes and no shoes.
|
Measurements will take at the first day of the visit
|
|
Height
Time Frame: Measurements will take at the first day of the visit
|
Measured by seca 217 stable stadiometer.
Subjects wearing no shoes.
|
Measurements will take at the first day of the visit
|
|
Waist and Hip circumferences
Time Frame: Measurements will take at the first day of the visit
|
Waist and Hip circumferences will be measured using a whole body laser scanner.
|
Measurements will take at the first day of the visit
|
|
Resting Metabolism
Time Frame: Measurements will take at the first day of the visit.
|
Resting energy expenditure will be measured using indirect calorimetry via a respiratory hood system (Cosmed).
The subject attends the lab after an overnight fast.
The person lies down on a flatbed and the hood is placed over their head.
Metabolic rates (oxygen consumption and CO2 production) are monitored for 30 minutes.
Calorimeters will be assessed with a turbine test to ensure the accuracy of measurements.
Validation via an alcohol burn will be performed monthly.
|
Measurements will take at the first day of the visit.
|
|
Fat mass
Time Frame: Measurements will take at the first day of the visit
|
Fat mass will be measured by Magnetic Resonance Imaging (Shanghai united imaging, uMR 790 ) or DXA (Hologic).
|
Measurements will take at the first day of the visit
|
|
Far free mass
Time Frame: Measurements will take at the first day of the visit
|
Fat free mass will be measured by Bioimpedance Analysis (Tanita, MC-980) or DXA (Hologic).
|
Measurements will take at the first day of the visit
|
|
Bone mass
Time Frame: Measurements will take at the first day of the visit
|
Bone mass will be measured by DXA (Hologic).
|
Measurements will take at the first day of the visit
|
|
Physical activity
Time Frame: Measurements last for 14 days
|
Physical activity of the participants will be recorded using GT3X accelerometer worn near the hip for a consecutive period of 14 days.
The monitor should not be worn while bathing or swimming.
The first day is discarded along with any day where the wear time is less than 10 hours.
For a valid measure, the goal is to get at least 2 weekday and 2 weekend days.
|
Measurements last for 14 days
|
|
Thyroid hormone
Time Frame: Blood samples will collect at the first day of the visit.
|
Nurses will collect the blood samples on day 1.
Levels of circulating thyroid hormones will be measured using radio immunoassay.
|
Blood samples will collect at the first day of the visit.
|
|
Resting Metabolism
Time Frame: measurements will take at the first day of visit
|
The whole room calorimeter/metabolic chamber (OMNICAL, Maastricht instrument) will be used to measure resting metabolic rate.
The metabolic chamber is a sealed room with a continuous gas supply (CO2- 0.80×10-2, O2 -18.00×10-2), providing subjects with 24-hour energy expenditure data.
The total energy expenditure of the subjects in MJ/day was plotted against time in 30-minute intervals over 24 hours.
The lowest and most stable energy expenditure during sleep time was considered the RMR of the subjects, which occurred from 2:00 am to 5:00 am.
|
measurements will take at the first day of visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total energy expenditure
Time Frame: Measurements take for 14 days
|
Total energy expenditure (TEE) will be measured using the DLW method.
Urine samples from all participants in the DLW subset will be stored at -20 oC and analyzed in the laboratory of Dr. John Speakman at the Shenzhen Institute of Advanced Technology, Chinese Academy of sciences.
Isotopes will be measured in a benchtop near-infrared isotope gas analyzer, and mean CO2 production will be calculated from isotope ratios using the recently derived equation (Speakman et al 2021: Cell reports medicine).
TEE will then be calculated using mean CO2 production using the Weir equation.
|
Measurements take for 14 days
|
|
Total energy expenditure
Time Frame: Measurements take at the first day of the visit
|
Total energy expenditure will be measured using the whole room calorimeter / metabolic chamber (OMNICAL, Maastricht instrument).
The metabolic chamber is a sealed room with a continuous gas supply (CO2- 0.80×10-2, O2 -18.00×10-2), providing subjects with 24-hour energy expenditure data.
The total energy expenditure was calculated by averaging the chamber's gaseous exchange using a 24-hour time window between 11.30 am and the next day around 3.00 pm.
|
Measurements take at the first day of the visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: John R Speakman, PhD, Shenzhen Institute of Advanced Technology, CAS
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 29, 2024
Primary Completion (Actual)
October 31, 2024
Study Completion (Actual)
January 31, 2025
Study Registration Dates
First Submitted
April 17, 2024
First Submitted That Met QC Criteria
April 17, 2024
First Posted (Actual)
April 22, 2024
Study Record Updates
Last Update Posted (Estimated)
August 15, 2025
Last Update Submitted That Met QC Criteria
August 11, 2025
Last Verified
August 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SIAT-IRB-240415-H0718
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thyroid
-
AllerganCompletedHypothyroidism | Thyroid Disease | Euthyroid | Thyroid Gland | Thyroid HormonesUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI); University of MichiganCompletedThyroid Cancer | Thyroid Nodule | Benign Thyroid NoduleUnited States
-
Imperial College LondonActive, not recruitingThyroid Cancer | Nodule Solitary ThyroidUnited Kingdom
-
Aarhus University HospitalOdense University Hospital; University of AarhusActive, not recruitingThyroid Cancer | Thyroid Nodule (Diagnosis)Denmark
-
National Cancer Institute (NCI)TerminatedInsular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid CancerUnited States
-
Tseung Kwan O Hospital, Hong KongRecruitingBenign Thyroid Nodule | Suspicious Malignant Thyroid NoduleHong Kong
-
Second Affiliated Hospital of Nanchang UniversitySun Yat-sen University; Beijing Friendship Hospital; Zhejiang University; General... and other collaboratorsActive, not recruitingThyroid | Thyroid Cancer | Thyroid AbnormalitiesChina
-
Sound Blade Medical Inc.Not yet recruitingThyroid Nodules | Thyroid Abnormalities
-
Wuhan UniversityRecruitingThyroid Carcinoma | Thyroid Nodule (Benign) | Ablation; RetinaChina
-
Maria Sklodowska-Curie National Research Institute...CompletedThyroid Cancer | Thyroid Nodule | Thyroid NeoplasmPoland